Targeting paraoxonase-1 in atherosclerosis (Q38097853)

28 August 2017

Targeting paraoxonase-1 in atherosclerosis (English)

1 reference

28 August 2017

1 reference

Mike Mackness

1

1 reference

PubMed ID

23573876

28 August 2017

Bharti Mackness

series ordinal

2

1 reference

PubMed ID

23573876

28 August 2017

language of work or name

English

0 references

publication date

10 April 2013

1 reference

Expert Opinion on Therapeutic Targets

28 August 2017

1 reference

28 August 2017

17

1 reference

28 August 2017

7

1 reference

28 August 2017

829-837

1 reference

28 August 2017

Human serum paraoxonase

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Serum esterases. II. An enzyme hydrolysing diethyl p-nitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Free radicals, lipoproteins and cardiovascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

High-density lipoprotein function, dysfunction, and reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

HDL, its enzymes and its potential to influence lipid peroxidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Determinants of paraoxonase 1 status: genes, drugs and nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase-1 is not associated with coronary artery calcification in type 2 diabetes: results from the PREDICT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Additional Common Polymorphisms in the PON Gene Cluster Predict PON1 Activity but Not Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Determination of paraoxonase 1 status without the use of toxic organophosphate substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

The paraoxonases: role in human diseases and methodological difficulties in measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: The PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.790367

10.1517/14728222.2013.790367

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23573876